One-Year Growth Hormone Therapy Improves Granulocyte Function without Major Effects on Nutritional and Anthropometric Parameters in Malnourished Hemodialysis Patients

2004 ◽  
Vol 93 (2) ◽  
pp. c75-c82 ◽  
Author(s):  
Harald Kotzmann ◽  
Alice Schmidt ◽  
Piero Lercher ◽  
Ernst Schuster ◽  
Georg Geyer ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Growth Hormone Therapy ◽  
Hemodialysis Patients ◽  
Anthropometric Parameters ◽  
One Year ◽  
Granulocyte Function

scholarly journals Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jing Wu ◽  
Fei Zhao ◽  
Yuan Zhang ◽  
Jiang Xue ◽  
Jiangying Kuang ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Treatment ◽  
Growth Hormone Therapy ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Hormone Treatment ◽  
Risk Markers ◽  
One Year

It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001). GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.

One-year recombinant growth hormone therapy does not improve hemoglobin state and morphology of erythrocytes in growth hormone deficient children

2018 ◽  
Vol 25 (1) ◽  
pp. 13-17 ◽  
Author(s):  
Maria Pankratova ◽  
Alexander Yusipovich ◽  
Maria Vorontsova ◽  
Evgenia Parshina ◽  
Svetlana Bochkareva ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Growth Hormone Therapy ◽  
Recombinant Growth Hormone ◽  
One Year

Effect of one-year growth hormone therapy on body composition and cardio-metabolic risk in Indian children with growth hormone deficiency

2013 ◽  
Vol 39 (2) ◽  
pp. 74-79 ◽  
Author(s):  
Vaman Khadilkar ◽  
Veena Ekbote ◽  
Neha Kajale ◽  
Anuradha Khadilkar ◽  
Shashi Chiplonkar ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Body Composition ◽  
Hormone Therapy ◽  
Growth Hormone Deficiency ◽  
Growth Hormone Therapy ◽  
Hormone Deficiency ◽  
Metabolic Risk ◽  
Indian Children ◽  
One Year

scholarly journals Differential effects of growth hormone therapy in malnourished hemodialysis patients

2001 ◽  
Vol 60 (4) ◽  
pp. 1578-1585 ◽  
Author(s):  
Harald Kotzmann ◽  
Nilgün Yilmaz ◽  
Piero Lercher ◽  
Michaela Riedl ◽  
Alice Schmidt ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Growth Hormone Therapy ◽  
Hemodialysis Patients ◽  
Differential Effects

scholarly journals A second KIGS communication on side effects of growth hormone therapy

1993 ◽  
Vol 39 (5) ◽  
pp. 85-88
Author(s):  
P. J. Chatlein ◽  
P. Wilton
Keyword(s):  
Growth Hormone ◽  
Side Effects ◽  
Brain Tumors ◽  
Hormone Therapy ◽  
Bone Tissue ◽  
Growth Hormone Therapy ◽  
Gh Therapy ◽  
One Year

By March 25, 1992, among the 16,604 patients included in the KIGS database who had been treated with growth hormone (GH) for at least one year, 135 had serious side effects (SE). Among the most frequent SE are relapses of craniopharyngioma (17) and other brain tumors (11). Changes in bone tissue, joints and muscles were more rarely observed. 7 patients had convulsive syndrome. More information is needed to assess the effect of GH therapy on these complications.

Efficacy and safety of one year of growth hormone therapy in steroid-dependent nephrotic syndrome

1997 ◽  
Vol 130 (5) ◽  
pp. 793-799 ◽  
Author(s):  
Kah Yin Loke ◽  
Hui Kim Yap ◽  
Xin Zhou ◽  
Siew Pin Tan ◽  
Sing Ming Chao ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Nephrotic Syndrome ◽  
Hormone Therapy ◽  
Growth Hormone Therapy ◽  
Efficacy And Safety ◽  
Steroid Dependent ◽  
One Year ◽  
Steroid Dependent Nephrotic Syndrome

Does growth hormone therapy increase the frequency of tumor recurrence in children with brain tumors?

1987 ◽  
Vol 116 (3_Suppl) ◽  
pp. S188-S189 ◽  
Author(s):  
K.P. RODENS ◽  
S.L. KAPLAN ◽  
M.M. GRUMBACH ◽  
W.M. TELLER
Keyword(s):  
Growth Hormone ◽  
Brain Tumors ◽  
Hormone Therapy ◽  
Tumor Recurrence ◽  
Growth Hormone Therapy
Sign in / Sign up

Export Citation Format

Share Document